Interferon-α for patients with chronic hepatitis delta: A systematic review of randomized clinical trials

Antiviral Therapy

Volumn 17, Issue 6, 2012, Pages 1029-1037

  Lamers, Mieke H ^a   Kirgiz, Özlem Özentürk ^a   Heidrich, Benjamin ^b   Wedemeyer, Heiner ^b   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA; PLACEBO; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DELTA AGENT HEPATITIS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FLU LIKE SYNDROME; HUMAN; INTERVENTION STUDY; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84865714110     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2306     Document Type: Article

References (60)

1. Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 1977; 18:997-1003.
2. Bonino F, Negro F, Baldi M, et al. The natural history of chronic delta hepatitis. Prog Clin Biol Res 1987; 234:145-152.
3. Le Gal F, Gault E, Ripault MP, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis 2006; 12:1447-1450.
4. Wu JC, Chen CM, Sheen IJ, Lee SD, Tzeng HM, Choo KB. Evidence of transmission of hepatitis D virus to spouses from sequence analysis of the viral genome. Hepatology 1995; 22:1656-1660.
5. Ivaniushina V, Radjef N, Alexeeva M, et al. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J Gen Virol 2001; 82:2709-2718.
6. Sakugawa H, Nakasone H, Nakayoshi T, et al. Hepatitis delta virus genotype IIb predominates in an endemic area, Okinawa, Japan. J Med Virol 1999; 58:366-372.
7. Watanabe H, Nagayama K, Enomoto N, et al. Chronic hepatitis delta virus infection with genotype IIb variant is correlated with progressive liver disease. J Gen Virol 2003; 84:3275-3289.
8. Wu JC, Chiang TY, Sheen IJ. Characterization and phylogenetic analysis of a novel hepatitis D virus strain discovered by restriction fragment length polymorphism analysis. J Gen Virol 1998; 79:1105-1113.
9. Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A 1993; 90:9016-9020.
10. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378:73-85.
11. Rizzetto M. Hepatitis D: virology, clinical and epidemiological aspects. Acta Gastroenterol Belg 2000; 63:221-224.
12. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39 Suppl 1:S212-S219.
13. Hsieh TH, Liu CJ, Chen DS, Chen PJ. Natural course and treatment of hepatitis D virus infection. J Formos Med Assoc 2006; 105:869-881.
14. Romeo R, Del NE, Rumi M, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136:1629-1638.
15. Smedile A, Dentico P, Zanetti A, et al. Infection with the delta agent in chronic HBsAg carriers. Gastroenterology 1981; 81:992-997.
16. Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet 1982; 320:945-947.
17. Grabowski J, Wedemeyer H. Hepatitis delta: immunopathogenesis and clinical challenges. Dig Dis 2010; 28:133-138.
18. Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol 2010; 53:834-840.
19. Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat 2011; 18:434-442.
20. Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 2010; 52:658-664.
21. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46:420-426.
22. Marinucci G, Hassan G, Di Giacomo C, et al. Long term treatment of chronic delta hepatitis with alpha recombinant interferon. Prog Clin Biol Res 1991; 364:405-410.
23. Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13:1052-1056.
24. Rosina F, Saracco G, Lattore V, Quarterone V, Rizzetto M, Verme G. Alpha 2 recombinant interferon in the treatment of chronic hepatitis delta virus (HDV) hepatitis. Prog Clin Biol Res 1987; 234:299-303.
25. Porres JC, Carreno V, Bartolome J, Moreno A, Galiana F, Quiroga JA. Treatment of chronic delta infection with recombinant human interferon alpha 2c at high doses. J Hepatol 1989; 9:338-344.
26. Di Bisceglie AM, Martin P, Lisker-Melman M, et al. Treatment of chronic delta hepatitis with interferon alfa-2b: pilot study conducted at NIH. J Hepatol 1990; 11 Suppl 1:S151-S154.
27. Hoofnagle J, Mullen K, Peters M, et al. Treatment of chronic delta hepatitis with recombinant human alpha interferon. Prog Clin Biol Res 1987; 234:291-298.
28. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330:88-94.
29. Madejón A, Cotonat T, Bartolome J, Castillo I, Carreno V. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994; 19:1331-1336.
30. Di Marco V, Giacchino R, Timitilli A, et al. Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study. J Viral Hepat 1996; 3:123-128.
31. Gaudin JL, Faure P, Godinot H, Gerard F, Trepo C. The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver 1995; 15:45-52.
32. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33:433-438.
33. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
34. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55:1350-1359.
35. Lutz HH, Trautwein C. Reviving pegylated interferon as a therapeutic agent for hepatitis D: no more room for nucleos(t)ides? Hepatology 2011; 53:2131-2134.
36. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322-331.
37. Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22:227-232.
38. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008; 15:314-321.
39. Yurdaydin C, Bozkaya H, Gurel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37:266-271.
40. Zavaglia C, Bottelli R, Smedile A, et al. A pilot study of thymosin-alpha 1 therapy for chronic hepatitis D. J Clin Gastroenterol 1996; 23:162-163.
41. Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994; 14:154-157.
42. Arrigoni A, Ponzetto A, Actis G, Bonino F. Levamisole and chronic delta hepatitis. Ann Intern Med 1983; 98:1024.
43. Higgins JPH, Green S (Editors). Cochrane handbook for systematic reviews of interventions. Chichester, UK: John Wiley & Sons Ltd 2008.
44. Canbakan B, Senturk H, Tabak F, et al. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol 2006; 21:657-663.
45. Gunsar F, Akarca US, Ersoz G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005; 10:721-726.
46. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44:713-720.
47. Pegylated interferon to treat chronic hepatitis D; HIDIT II - PegIFN-alfa2a plus tenofovir in chronic delta hepatitis. Clinicaltrials.gov identifier NCT00932971. (Updated 23 June 2011. Accessed 1 July 2011.) Available from http://clinicaltrials.gov/ct2/show/NCT00932971
48. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005; 12:2-9.
49. Sagnelli E, Stroffolini T, Ascione A, et al. Decrease in HDV endemicity in Italy. J Hepatol 1997; 26:20-24.
50. Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology 2000; 32:824-827.
51. Navascués CA, Rodriguez M, Sotorrio NG, et al. Epidemiology of hepatitis D virus infection: changes in the last 14 years. Am J Gastroenterol 1995; 90:1981-1984.
52. Glenn JS. Prenylation of HDAg and antiviral drug development. Curr Top Microbiol Immunol 2006; 307:133-149.
53. Bordier BB, Ohkanda J, Liu P, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003; 112:407-414.
54. Proof-of-concept study evaluating the safety and efficacy of EBP921 in delta hepatitis (HDV). Clinicaltrials.gov identifier NCT01316185. (Updated 14 March 2011. Accessed 1 July 2011.) Available from http://clinicaltrials.gov/ct2/ show/NCT01316185?term=Proof-of- concept+study+evaluating+the+safety+and+efficacy+of+EBP921+in+delta+hepatitis. &rank=1
55. Kabacam G, Yakut M, Seven G, Bozkaya H, Idilman R, Yurdaydin C. Interferon treatment of delta hepatitis: the longer the duration the better the success? J Hepatol 2011; 54 Suppl 1:S290.
56. Mederacke I, Bremer B, Heidrich B, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48:2022-2029.
57. Aoki YH, Ohkoshi S, Yamagiwa S, et al. Characterization of elevated alanine aminotransferase levels during pegylated-interferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Hepatol Res 2011; 41:118-125.
58. Rizzetto M, Rosina F, Saracco G, et al. Treatment of chronic delta hepatitis with alpha-2 recombinant interferon. J Hepatol 1986; 3 Suppl 2:S229-S233.
59. Gaudin JL, Trepo C. Therapy of chronic delta hepatitis with alpha- and beta-interferon. Prog Clin Biol Res 1993; 382:345-352.
60. Rosina F, Pintus C, Meschievitz C, Rizzetto M. Long term interferon treatment of chronic delta hepatitis: a multicenter Italian study. Prog Clin Biol Res 1991; 364:385-391.